Deals channel feed – Endpoints News

Deals channel feed

Pfizer fronts $250M to nab antisense drug from Akcea/Ionis in up to $1.5B deal

6 years ago

Vivek Ramaswamy engineers new deal with RTW to take Pete Salzmann's Immunovant public

6 years ago

As its oncology effort gathers steam, AstraZeneca sheds another legacy drug

6 years ago

Failed NewLink goes dark in a reverse merger, as Lumos jumps on board for a ride to Wall Street

6 years ago

Roche sets new deadline for Spark acquisition as divestiture speculation brews

6 years ago

Vertex continues shopping, spending $20M upfront to access Ribometrix's RNA-drugging platform

6 years ago

Dova Pharma's bet on Eisai castoff spells gold as Sobi spends millions to acquire it

6 years ago

Another big biopharma merger runs into another snag at the FTC. What now?

6 years ago

Is the FTC about to force Roche to divest a key hemophilia program before green-lighting Spark buyout?

6 years ago

Regulators throw up another hurdle to Roche’s $4.3B Spark acquisition as questions percolate over hemophilia market domination

6 years ago

Coming out of Chapter 11, Aegerion jumps into welcome arms of Irish pharma with big plans, fresh $60M for its drugs

6 years ago

Ex-Retrophin BD chief flips his rare disease startup onto Nasdaq via reverse merger with Proteon

6 years ago

Lundbeck’s Deborah Dunsire didn’t just want an ex-US deal for Alder’s migraine drug. She wanted the whole world

6 years ago

A long-suffering Clovis makes a leap into radiopharmaceuticals, paying $12M in cash to beef up the pipeline

6 years ago

Boehringer Ingelheim enlists another virtual biotech partner for its foray into retinal diseases

6 years ago

Deborah Dunsire is paying $2B for a chance to leap directly into a blockbuster showdown with a few of the world's biggest pharma giants

6 years ago

From partner to knight in shining armor: Castle Creek to buy Fibrocell

6 years ago

Another pharma giant makes a leap into the global medical marijuana business

6 years ago

Atomwise inks China deal as list of AI collaborations lengthens

6 years ago

After plenty of due diligence, GSK buys one biotech pup in the ‘$500M’ Avalon litter for its pipeline

6 years ago

Australian cell therapy company Mesoblast joins forces with Germany's Grünenthal to tackle low back pain

6 years ago

Shedding non-core units while loading up on cash, Mallinckrodt bags $250M in CDMO sale

6 years ago

Roivant's Vivek Ramaswamy is closing in on a $3B cash deal to sell control of 5 Vants — plus — to Sumitomo Dainippon

6 years ago

Private equity meets China biotech: PAG infuses $540M to gain control of Hisun's biosimilar subsidiary

6 years ago

First page Previous page 98 99 100101102 103 104 Next page Last page